Search Orphan Drug Designations and Approvals
-
| Generic Name: | a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human MYBPC3 gene |
|---|---|
| Date Designated: | 05/12/2021 |
| Orphan Designation: | Treatment of hypertrophic cardiomyopathy (HCM) due to loss-of-function mutations in the MYBPC3 gene encoding cardiac myosin-binding protein C |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Tenaya Therapeutics 701 Oyster Point Blvd Suite 500 South San Francisco, California 94080 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







